JP2013506684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506684A5 JP2013506684A5 JP2012532316A JP2012532316A JP2013506684A5 JP 2013506684 A5 JP2013506684 A5 JP 2013506684A5 JP 2012532316 A JP2012532316 A JP 2012532316A JP 2012532316 A JP2012532316 A JP 2012532316A JP 2013506684 A5 JP2013506684 A5 JP 2013506684A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- wall fragility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000010339 dilation Effects 0.000 claims description 13
- 230000002792 vascular Effects 0.000 claims description 13
- 229940124761 MMP inhibitor Drugs 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000005541 ACE inhibitor Substances 0.000 claims description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 7
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 7
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 6
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 6
- 239000003087 receptor blocking agent Substances 0.000 claims description 6
- 206010002329 Aneurysm Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 3
- 210000000115 thoracic cavity Anatomy 0.000 claims description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
- 108010072220 Cyclophilin A Proteins 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- -1 aprosartan Chemical compound 0.000 claims description 2
- 229960004530 benazepril Drugs 0.000 claims description 2
- 229960000932 candesartan Drugs 0.000 claims description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960002490 fosinopril Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- 229960001455 quinapril Drugs 0.000 claims description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 2
- 229960003401 ramipril Drugs 0.000 claims description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 229960002769 zofenopril Drugs 0.000 claims description 2
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 description 17
- 241000124008 Mammalia Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- GDCJGAQDVGMSOF-ZUALZJRYSA-N COCCNC(N(CC1)C[C@H](C(NO)=O)N1S(c(cc1F)cc(F)c1Oc(cc1)ccc1Cl)=O)=N Chemical compound COCCNC(N(CC1)C[C@H](C(NO)=O)N1S(c(cc1F)cc(F)c1Oc(cc1)ccc1Cl)=O)=N GDCJGAQDVGMSOF-ZUALZJRYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000000134 cyclophilin inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24784309P | 2009-10-01 | 2009-10-01 | |
| US61/247,843 | 2009-10-01 | ||
| PCT/US2010/050907 WO2011041545A1 (en) | 2009-10-01 | 2010-09-30 | Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013506684A JP2013506684A (ja) | 2013-02-28 |
| JP2013506684A5 true JP2013506684A5 (cg-RX-API-DMAC7.html) | 2013-10-31 |
Family
ID=43034492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532316A Pending JP2013506684A (ja) | 2009-10-01 | 2010-09-30 | マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110082114A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2482817A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013506684A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102639134A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2774389A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011041545A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013506684A (ja) * | 2009-10-01 | 2013-02-28 | シンフォニー エボリューション， インコーポレイテッド | マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法 |
| US9629891B2 (en) | 2011-10-17 | 2017-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| EP3693460A1 (en) * | 2012-07-27 | 2020-08-12 | Ionis Pharmaceuticals, Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| WO2014028334A1 (en) * | 2012-08-11 | 2014-02-20 | Symphony Evolution, Inc. | Selective mmp inhibitors |
| US9791461B2 (en) | 2012-10-30 | 2017-10-17 | Tohoku University | Method for testing for cardiovascular disease with cyclophilin A |
| BR122020023854B1 (pt) | 2015-10-08 | 2022-11-29 | Ionis Pharmaceuticals, Inc | Composto compreendendo oligonucleotídeo modificado e seu uso, uso do oligonucleotídeo modificado, composição e seu uso |
| US11376248B2 (en) * | 2017-06-30 | 2022-07-05 | Georgia State University Research Foundation, Inc. | Treatment of aneurysms |
| CN107417629B (zh) * | 2017-08-09 | 2020-02-07 | 苏州楚凯药业有限公司 | 动脉瘤抑制剂xl784的制备方法 |
| US11273148B2 (en) | 2017-09-01 | 2022-03-15 | The Johns Hopkins University | Targeted epigenetic therapy for inherited aortic aneurysm condition |
| CN108947850B (zh) * | 2018-07-23 | 2021-05-18 | 蚌埠中实化学技术有限公司 | 一种3,4,5-三氟苯胺的制备方法 |
| WO2021063366A1 (zh) * | 2019-09-30 | 2021-04-08 | 中国科学院上海药物研究所 | 用于治疗动脉相关疾病的药物及其用途 |
| CN111500721B (zh) * | 2020-04-20 | 2022-11-29 | 青岛大学附属医院 | Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用 |
| ES2990026T3 (es) | 2020-11-18 | 2024-11-28 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular la expresión del angiotensinógeno |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723836B2 (en) | 1996-08-29 | 2000-09-07 | Regents Of The University Of California, The | Kuz, a novel family of metalloproteases |
| US5922546A (en) | 1997-08-25 | 1999-07-13 | Smithkline Beecham Corporation | Human disintegrin metalloprotease KUZ gene |
| ATE225187T1 (de) * | 1997-12-23 | 2002-10-15 | Warner Lambert Co | Ace hemmer/matrix metalloproteinase hemmer- arzneimittelkombinationen |
| AUPP584198A0 (en) * | 1998-09-14 | 1998-10-08 | Fujisawa Pharmaceutical Co., Ltd. | New use |
| AU2002241343A1 (en) * | 2002-03-29 | 2003-10-13 | Anges Mg, Inc. | Decoy compositions for treating and preventing brain diseases and disorders |
| AU2003237532B2 (en) | 2002-06-12 | 2009-07-30 | Symphony Evolution, Inc. | Human ADAM-10 inhibitors |
| US7396540B2 (en) * | 2003-04-25 | 2008-07-08 | Medtronic Vascular, Inc. | In situ blood vessel and aneurysm treatment |
| US7371228B2 (en) * | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
| US20050266043A1 (en) * | 2004-05-27 | 2005-12-01 | Medtronic Vascular, Inc. | Methods and compounds for treatment of aneurysmal tissue |
| WO2007016482A2 (en) * | 2005-07-29 | 2007-02-08 | Imperial Innovations Limited | Mutant timp-3 |
| US8597646B2 (en) * | 2005-10-25 | 2013-12-03 | The Johns Hopkins University | Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders |
| JP2013506684A (ja) * | 2009-10-01 | 2013-02-28 | シンフォニー エボリューション， インコーポレイテッド | マトリックスメタロプロテアーゼ−２阻害剤を用いた、動脈瘤性拡張、血管壁脆弱性、特に腹部大動脈瘤および胸部動脈瘤を治療する方法 |
-
2010
- 2010-09-30 JP JP2012532316A patent/JP2013506684A/ja active Pending
- 2010-09-30 US US12/895,073 patent/US20110082114A1/en not_active Abandoned
- 2010-09-30 EP EP10762834A patent/EP2482817A1/en not_active Withdrawn
- 2010-09-30 WO PCT/US2010/050907 patent/WO2011041545A1/en not_active Ceased
- 2010-09-30 CA CA2774389A patent/CA2774389A1/en not_active Abandoned
- 2010-09-30 US US13/497,726 patent/US20120270884A1/en not_active Abandoned
- 2010-09-30 CN CN2010800545319A patent/CN102639134A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506684A5 (cg-RX-API-DMAC7.html) | ||
| Aulakh et al. | An update on non-peptide angiotensin receptor antagonists and related RAAS modulators | |
| Cacciapuoti | Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)—possible therapeutic perspectives | |
| JP2004513920A5 (cg-RX-API-DMAC7.html) | ||
| Unger | Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| GT200600055A (es) | Combinación de compuestos organicos | |
| JP2008508279A5 (cg-RX-API-DMAC7.html) | ||
| JP2016502526A5 (cg-RX-API-DMAC7.html) | ||
| JP2018504436A5 (cg-RX-API-DMAC7.html) | ||
| Shin et al. | 2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations | |
| CN106163518B (zh) | 包含血管紧张素-Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的药物组合制剂 | |
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| A Fraga-Silva et al. | Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture | |
| JP2016520135A5 (cg-RX-API-DMAC7.html) | ||
| CN105025895A (zh) | 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物 | |
| US20210023088A1 (en) | Reducing the risk of cardiovascular events | |
| CN1271283A (zh) | 内皮素拮抗剂和血管紧张肽原酶－血管紧张肽系统抑制剂的药物组合物 | |
| Miura | The renin-angiotensin-aldosterone system: A new look at an old system | |
| Rivoli et al. | Pharmacological effects of RAAS blockade in ischemic nephropathy | |
| WO2010047559A3 (ko) | 방출성이 제어된 약제학적 제제 | |
| CA2993858C (en) | Combination of rivaroxaban and acetylsalicylic acid for reducing the risk of cardiovascular events | |
| JP2005511631A (ja) | 脳血管障害発作の急性期における高血圧症の治療 | |
| RU2010129473A (ru) | Фармацевтическая композиция для лечения и/или профилактики артериальной гипертензии | |
| Dashti-Khavidaki et al. | Cough induced by losartan with resolution after substitution with enalapril |